As of November 6, 2026, Alx Oncology Holdings Inc. is a publicly traded company (Nasdaq: ALXO). The largest holder reporting an active stake on Schedule 13D is venBio Global Strategic Fund, L.P., at 9.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include RA Capital (9.9%), Redmile Group, LLC (6.8%), HBM Healthcare Investments (Cayman) Ltd. (6.5%) (Schedule 13D/A, October 16, 2026).
Is this your company?
About to sign with, pay or invest in Alx Oncology Holdings Inc? See the free Snapshot first.
Free to see. No signup.
Is Alx Oncology Holdings Inc. a real, registered company?
- Alx Oncology Holdings Inc files with the SEC under CIK 1810182 (its SEC filings).
- Its shares are listed under the ticker ALXO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ALX ONCOLOGY HOLDINGS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Corey Goodman (Form 8-K filed 2026-06-30). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names venBio Global Strategic Fund, L.P. (filed 2026-10-16).
Who are Alx Oncology Holdings Inc.'s owners and officers?
Alx Oncology Holdings Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-10-16).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-10-16 | Venbio Global Strategic Fund, L.P. | 9.99% |
| Schedule 13G/A, 2026-08-14 | Chen Yu | 4.2% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 5.4% |
| Schedule 13D/A, 2026-05-27 | Lsv Associates, LLC | 2.2% |
| Schedule 13G/A, 2026-05-15 | Hbm Healthcare Investments (Cayman) LTD. | 6.5% |
| Schedule 13G/A, 2026-05-15 | Redmile Group, LLC | 6.8% |
| Schedule 13G/A, 2026-04-28 | Millennium Management LLC | 1.5% |
| Schedule 13G, 2026-02-09 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G, 2026-02-06 | Chen Yu | 9.9% |
| Schedule 13D/A, 2026-02-04 | Venbio Global Strategic Fund, L.P. | 10% |
| Schedule 13G/A, 2025-11-14 | Tang Capital Management, LLC | 0% |
| Schedule 13G/A, 2025-11-14 | Tang Capital Management, LLC | 0% |
Questions about who owns Alx Oncology Holdings Inc.
Who owns Alx Oncology Holdings Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Alx Oncology Holdings Inc.: Venbio Global Strategic Fund, L.P. (9.99%, Schedule 13D/A, filed 2026-10-16), Ra Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-02-09), Redmile Group, LLC (6.8%, Schedule 13G/A, filed 2026-05-15), Hbm Healthcare Investments (Cayman) LTD. (6.5%, Schedule 13G/A, filed 2026-05-15) and Blackrock, Inc. (5.4%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Alx Oncology Holdings Inc.?
By the share each holder's latest filing reports, the largest holders of Alx Oncology Holdings Inc. on this page are Venbio Global Strategic Fund, L.P. (9.99%), Ra Capital Management, L.P. (9.9%) and Redmile Group, LLC (6.8%).
When did Venbio Global Strategic Fund, L.P. buy into Alx Oncology Holdings Inc.?
The filings give report dates, not purchase dates. The earliest filing from Venbio Global Strategic Fund, L.P. on this page is the Schedule 13D/A, filed 2026-02-04, reporting 10%; its latest, Schedule 13D/A filed 2026-10-16, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Alx Oncology Holdings Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alx Oncology Holdings Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alx Oncology Holdings Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-30 | Corey Goodman | departed | ||
| Form 8-K, 2026-04-13 | Jeff Knight | Chief Development and Operating Officer | appointed | 2026-04-13 |
Which insiders own Alx Oncology Holdings Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 8,453,038 shares (6.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-02-04).
- , the president and cso: 579,388 shares (0.42% of shares outstanding) (Form 4, 2025-02-21).
- , the chief executive and a director: 294,379 shares (0.21% of shares outstanding) (Form 4, 2026-08-18).
- , the chief medical officer: 120,000 shares (0.09% of shares outstanding), 60,000 held directly and 60,000 indirectly (Form 3, 2026-03-05).
- , the senior vice president and finance: 87,828 shares (0.06% of shares outstanding) (Form 4, 2026-08-18).
Shares outstanding: 138,276,997 as of 2026-07-30, from the company's latest SEC cover page.
How much has Alx Oncology Holdings Inc. raised?
No fundraising or offering filing from Alx Oncology Holdings Inc. is on file with us.
Keep reading
More on Alx Oncology Holdings Inc and the records around it.
Alx Oncology Holdings Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jun 2026
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), IO Biotech, Inc. (Apr 2026), Upstream Bio, Inc. (Nov 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026), LB Pharmaceuticals Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/alx-oncology